Hormonal adjuvant therapy should not be recommended to women whose breast cancers do not express hormone receptor protein
2002
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
Key concepts
Scholarcy highlights
- Hormonal adjuvant therapy should not be recommended to women whose breast cancers do not express hormone receptor protein
- Available data demonstrate that chemotherapy and tamoxifen are additive in their impact on survival when employed as adjuvant treatment of breast cancer
- During the past 10 years, substantial progress has been made in the treatment of breast cancer
- Mortality rates for breast cancer are decreasing in the United States
- Refinements of adjuvant treatment have contributed to this advance
- Ph.D. Associate Professor of Biostatistics University of Pittsburgh Director, Biostatistical Center National Surgical Adjuvant Breast and Bowel
Need more features? Save interactive summary cards to your Scholarcy Library.